BD
MCID: BHC003
MIFTS: 75

Behcet Syndrome (BD)

Categories: Bone diseases, Cardiovascular diseases, Eye diseases, Nephrological diseases, Neuronal diseases, Rare diseases, Skin diseases

Aliases & Classifications for Behcet Syndrome

MalaCards integrated aliases for Behcet Syndrome:

Name: Behcet Syndrome 58 12 77 54 26 45 39 74
Behcet's Syndrome 12 54 26 6 44 17
Behcet's Disease 39 12 54 55 15
Behcet Disease 58 26 38 56
Behçet Disease 54 26 60
Adamantiades-Behcet Disease 12 26
Triple Symptom Complex 12 26
Bd 58 54
Behcet Triple Symptom Complex 26
Old Silk Route Disease 26
Malignant Aphthosis 26
Behcet Disease; Bd 58
Behçet's Syndrome 54
Behet's Syndrome 12
Behçet's Disease 54
Syndrome, Behcet 41
Behçet Syndrome 54

Characteristics:

Orphanet epidemiological data:

60
behçet disease
Inheritance: Multigenic/multifactorial; Prevalence: 1-5/10000 (Japan),>1/1000 (Turkey); Age of onset: Adolescent,Adult,Childhood; Age of death: adult;

OMIM:

58
Inheritance:
familial cases reported, but probably not mendelian


Classifications:



Summaries for Behcet Syndrome

NIH Rare Diseases : 54 Behçet disease is a chronic multisystem inflammatory disorder characterized by ulcers affecting the mouth and genitals, various skin lesions, and abnormalities affecting the eyes. In some people, the disease also results in arthritis (swollen, painful, stiff joints), skin problems, and inflammation of the digestive tract, brain, and spinal cord. Although it can happen at any age, symptoms generally begin when individuals are in their 20s or 30s. The disease is common in Japan, Turkey and Israel, and less common in the United States. The exact cause of Behçet disease is still unknown, but it is thought that it is an autoimmune disease, where the abnormal immune activity is triggered by exposure to an environmental agent (such as an infection) in people with a genetic predisposition to develop the disease. Research show that people with Behçet�??s disease, especially those of Middle Eastern and Asian descent, have an increased frequency of certain �??human leukocyte antigens�?� (HLAs), specifically HLA-B51, than the general population, which may increase the risk (predispose) to have the disease.  Treatment is symptomatic and supportive. Research is being conducted on the use of interferon-alpha and with agents which inhibit tumor necrosis factor (TNF) for the treatment of Behçet disease. Behçet disease is a lifelong disorder that comes and goes. Spontaneous remission over time is common for individuals with Behçet disease but permanent remission of symptoms has not been reported.

MalaCards based summary : Behcet Syndrome, also known as behcet's syndrome, is related to chlamydia and vogt-koyanagi-harada disease, and has symptoms including angina pectoris, edema and pruritus. An important gene associated with Behcet Syndrome is MEFV (MEFV Innate Immuity Regulator, Pyrin), and among its related pathways/superpathways are Innate Immune System and Akt Signaling. The drugs Prednisolone phosphate and Prednisolone have been mentioned in the context of this disorder. Affiliated tissues include eye, skin and brain, and related phenotypes are nausea and vomiting and arthritis

Disease Ontology : 12 A vasculitis that is characterized by an autoimmune mediated inflammation of the blood vessels throughout the body leading to ulcerations on the mouth and sometimes the genitals, notorious for causing hypopyon uveitis.

Genetics Home Reference : 26 Behçet disease is an inflammatory condition that affects many parts of the body. The health problems associated with Behçet disease result from widespread inflammation of blood vessels (vasculitis). This inflammation most commonly affects small blood vessels in the mouth, genitals, skin, and eyes.

MedlinePlus : 44 Behcet's syndrome is a disease that involves vasculitis, which is inflammation of the blood vessels. It causes problems in many parts of the body. The most common symptoms are Sores in the mouth Sores on the sex organs Other skin sores Swelling of parts of the eye Pain, swelling and stiffness of the joints More serious problems can include meningitis, blood clots, inflammation of the digestive system and blindness. Doctors aren't sure what causes Behcet's. It is rare in the United States, but is common in the Middle East and Asia. It mainly affects people in their 20s and 30s. Diagnosing Behcet's can take a long time, because symptoms may come and go, and it may take months or even years to have all of the symptoms. There is no cure. Treatment focuses on reducing pain and preventing serious problems. Most people can control symptoms with treatment. NIH: National Institute of Arthritis and Musculoskeletal and Skin Diseases

NINDS : 55 Behcet's disease is a rare, chronic inflammatory disorder. The cause of Behcet's disease is unknown, but current research suggests that both genetic and  environmental factors play a role.  Behcet's disease generally begins when individuals are in their 20s or 30s, although it can happen at any age. It tends to occur more often in men than in women. Symptoms of Behcet's disease include recurrent ulcers in the mouth (resembling canker sores) and on the genitals, and eye inflammation. The disorder may also cause various types of skin lesions, arthritis, bowel inflammation, meningitis (inflammation of the membranes of the brain and spinal cord), and cranial nerve palsies. Behcet's is a multi-system disease; it may involve all organs and affect the central nervous system, causing memory loss and impaired speech, balance, and movement. The effects of the disease may include blindness, stroke, swelling of the spinal cord, and intestinal complications. The disease is common in the Middle East, particularly in Turkey, and in Far Eastern nations such as Japan and Korean, but is less common in the United States.

Wikipedia : 77 Behçet''s disease (BD) is a type of inflammatory disorder which affects multiple parts of the body. The... more...

Description from OMIM: 109650

Related Diseases for Behcet Syndrome

Diseases related to Behcet Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 503)
# Related Disease Score Top Affiliating Genes
1 chlamydia 31.1 CRP IL10 TLR4 TNF
2 vogt-koyanagi-harada disease 31.1 FAS HLA-B IL10
3 pyoderma 31.1 MEFV NOD2 PSTPIP1 TNF
4 pyoderma gangrenosum 31.1 MEFV NOD2 PSTPIP1 TNF
5 uveitis 31.1 HLA-B IL10 NOD2 TNF
6 arthritis 31.1 IL10 NOD2 PSTPIP1 STAT4 TNF
7 spondyloarthropathy 1 30.9 CRP HLA-B NOD2 TLR4 TNF
8 spondylitis 30.9 TNF NOD2 IL23R HLA-B ERAP1 CRP
9 aphthous stomatitis 30.8 HLA-B IL10 MEFV TNF
10 lupus erythematosus 30.8 C4A IL10 STAT4 TNF
11 meningitis 30.8 CRP IL10 TNF
12 colitis 30.8 IL10 IL23R NOD2 TLR4 TNF
13 vasculitis 30.8 CRP HLA-B MEFV TNF
14 brucellosis 30.8 TNF TLR4 MEFV IL10 CRP
15 familial mediterranean fever 30.8 TNFRSF1A TNF PSTPIP1 NOD2 MEFV CRP
16 crohn's disease 30.8 CRP IL10 IL23R NOD2 TNF
17 rheumatic disease 30.8 CRP HLA-B IL10 TNF
18 inflammatory bowel disease 30.7 TNF TLR4 STAT4 NOD2 IL23R IL10
19 ulcerative colitis 30.7 TNF TLR4 NOD2 IL23R IL10 CRP
20 bacterial meningitis 30.7 CRP IL10 TNF
21 systemic lupus erythematosus 30.7 C4A CRP FAS IL10 STAT4 TLR4
22 endocarditis 30.7 CRP IL10 TNF
23 takayasu arteritis 30.6 CRP HLA-B TNF
24 spondylarthropathy 30.6 NOD2 TLR4 TNF TNFRSF1A
25 hematopoietic stem cell transplantation 30.6 HLA-B IL10 TNF
26 pericarditis 30.6 CRP MEFV TNF TNFRSF1A
27 cytomegalovirus infection 30.6 CCR1 FAS HLA-B TNF
28 polyarteritis nodosa 30.6 ADA2 CRP MEFV
29 autoimmune disease 30.6 FAS IL10 STAT4 TNF
30 lymphadenitis 30.6 IL10 NOD2 TLR4 TNF
31 psoriatic arthritis 30.6 TNFRSF1A TNF NOD2 IL23R HLA-B CRP
32 complex regional pain syndrome 30.6 HLA-B IL10 TNF
33 periodontitis 30.5 CRP IL10 TLR4 TNF
34 pneumonia 30.5 CRP IL10 TLR4 TNF
35 rheumatoid arthritis 30.5 CRP HLA-B IL10 STAT4 TLR4 TNF
36 typhoid fever 30.5 CRP TLR4 TNF
37 pertussis 30.5 IL10 TLR4 TNF
38 toxoplasmosis 30.4 IL10 TLR4 TNF
39 atherosclerosis susceptibility 30.3 CRP TLR4 TNF
40 demyelinating disease 30.3 IL10 TNF TNFRSF1A
41 multiple sclerosis 30.2 CCR1 IL10 TNF TNFRSF1A
42 binswanger's disease 11.4
43 subcortical arteriosclerotic encephalopathy 11.4
44 dementia - subcortical 11.4
45 intellectual disability - athetosis - microphthalmia 11.4
46 boomerang dysplasia 11.3
47 diamond-blackfan anemia 1 11.3
48 spondyloepiphyseal dysplasia-brachydactyly and distinctive speech 11.3
49 brody myopathy 11.3
50 diamond-blackfan anemia 11.2

Graphical network of the top 20 diseases related to Behcet Syndrome:



Diseases related to Behcet Syndrome

Symptoms & Phenotypes for Behcet Syndrome

Human phenotypes related to Behcet Syndrome:

60 33 (show top 50) (show all 81)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 nausea and vomiting 60 33 hallmark (90%) Very frequent (99-80%) HP:0002017
2 arthritis 60 33 hallmark (90%) Very frequent (99-80%) HP:0001369
3 photophobia 60 33 hallmark (90%) Very frequent (99-80%) HP:0000613
4 fever 60 33 hallmark (90%) Very frequent (99-80%) HP:0001945
5 fatigue 60 33 hallmark (90%) Very frequent (99-80%) HP:0012378
6 subcutaneous nodule 60 33 hallmark (90%) Very frequent (99-80%) HP:0001482
7 migraine 60 33 hallmark (90%) Very frequent (99-80%) HP:0002076
8 myalgia 60 33 hallmark (90%) Very frequent (99-80%) HP:0003326
9 meningitis 60 33 hallmark (90%) Very frequent (99-80%) HP:0001287
10 vasculitis 60 33 hallmark (90%) Very frequent (99-80%) HP:0002633
11 papule 60 33 hallmark (90%) Very frequent (99-80%) HP:0200034
12 oral ulcer 60 33 hallmark (90%) Very frequent (99-80%) HP:0000155
13 recurrent aphthous stomatitis 60 33 hallmark (90%) Very frequent (99-80%) HP:0011107
14 orchitis 60 33 hallmark (90%) Very frequent (99-80%) HP:0100796
15 gait disturbance 60 33 frequent (33%) Frequent (79-30%) HP:0001288
16 arthralgia 60 33 frequent (33%) Frequent (79-30%) HP:0002829
17 abdominal pain 60 33 frequent (33%) Frequent (79-30%) HP:0002027
18 abnormal blistering of the skin 60 33 frequent (33%) Frequent (79-30%) HP:0008066
19 acne 60 33 frequent (33%) Frequent (79-30%) HP:0001061
20 venous thrombosis 60 33 frequent (33%) Frequent (79-30%) HP:0004936
21 gastrointestinal hemorrhage 60 33 frequent (33%) Frequent (79-30%) HP:0002239
22 immunologic hypersensitivity 60 33 frequent (33%) Frequent (79-30%) HP:0100326
23 confusion 60 33 frequent (33%) Frequent (79-30%) HP:0001289
24 hemiparesis 60 33 frequent (33%) Frequent (79-30%) HP:0001269
25 seizures 60 33 occasional (7.5%) Occasional (29-5%) HP:0001250
26 ataxia 60 33 occasional (7.5%) Occasional (29-5%) HP:0001251
27 hyperreflexia 60 33 occasional (7.5%) Occasional (29-5%) HP:0001347
28 developmental regression 60 33 occasional (7.5%) Occasional (29-5%) HP:0002376
29 encephalitis 60 33 occasional (7.5%) Occasional (29-5%) HP:0002383
30 cataract 60 33 occasional (7.5%) Occasional (29-5%) HP:0000518
31 splenomegaly 60 33 occasional (7.5%) Occasional (29-5%) HP:0001744
32 increased intracranial pressure 60 33 occasional (7.5%) Occasional (29-5%) HP:0002516
33 aseptic necrosis 60 33 occasional (7.5%) Occasional (29-5%) HP:0010885
34 malabsorption 60 33 occasional (7.5%) Occasional (29-5%) HP:0002024
35 blindness 60 33 occasional (7.5%) Occasional (29-5%) HP:0000618
36 renal insufficiency 60 33 occasional (7.5%) Occasional (29-5%) HP:0000083
37 retinopathy 60 33 occasional (7.5%) Occasional (29-5%) HP:0000488
38 cranial nerve paralysis 60 33 occasional (7.5%) Occasional (29-5%) HP:0006824
39 myocardial infarction 60 33 occasional (7.5%) Occasional (29-5%) HP:0001658
40 pulmonary embolism 60 33 occasional (7.5%) Occasional (29-5%) HP:0002204
41 irritability 60 33 occasional (7.5%) Occasional (29-5%) HP:0000737
42 weight loss 60 33 occasional (7.5%) Occasional (29-5%) HP:0001824
43 pancreatitis 60 33 occasional (7.5%) Occasional (29-5%) HP:0001733
44 anorexia 60 33 occasional (7.5%) Occasional (29-5%) HP:0002039
45 memory impairment 60 33 occasional (7.5%) Occasional (29-5%) HP:0002354
46 cerebral ischemia 60 33 occasional (7.5%) Occasional (29-5%) HP:0002637
47 paresthesia 60 33 occasional (7.5%) Occasional (29-5%) HP:0003401
48 glomerulopathy 60 33 occasional (7.5%) Occasional (29-5%) HP:0100820
49 keratoconjunctivitis sicca 60 33 occasional (7.5%) Occasional (29-5%) HP:0001097
50 abnormal myocardium morphology 60 33 occasional (7.5%) Occasional (29-5%) HP:0001637

Symptoms via clinical synopsis from OMIM:

58
Joints:
arthritis

Skin:
raynaud phenomenon
erythema nodosum-like eruptions
superficial thrombophlebitis
pustular skin lesions
hyperirritability

Mouth:
mouth ulcerations

Neuro:
brainstem syndrome
meningoencephalomyelitic syndrome
organic confusional state
schizoaffective disorder

Eyes:
uveitis
iritis
iridocyclitis
hypopyon
choreoretinitis

Hair:
alopecia areata

G U:
genital ulcerations
epididymitis

Clinical features from OMIM:

109650

UMLS symptoms related to Behcet Syndrome:


angina pectoris, edema, pruritus, chest pain, snoring, exanthema, halitosis, oral manifestations

GenomeRNAi Phenotypes related to Behcet Syndrome according to GeneCards Suite gene sharing:

27 (show top 50) (show all 65)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-100 10.24 IL10
2 Increased shRNA abundance (Z-score > 2) GR00366-A-101 10.24 CCR1
3 Increased shRNA abundance (Z-score > 2) GR00366-A-103 10.24 HLA-B
4 Increased shRNA abundance (Z-score > 2) GR00366-A-105 10.24 ADA2 CCR1
5 Increased shRNA abundance (Z-score > 2) GR00366-A-106 10.24 ADA2
6 Increased shRNA abundance (Z-score > 2) GR00366-A-107 10.24 ADA2 C4A
7 Increased shRNA abundance (Z-score > 2) GR00366-A-110 10.24 HLA-B
8 Increased shRNA abundance (Z-score > 2) GR00366-A-113 10.24 C4A CCR1 IL10 TLR4
9 Increased shRNA abundance (Z-score > 2) GR00366-A-114 10.24 TLR4
10 Increased shRNA abundance (Z-score > 2) GR00366-A-116 10.24 C4A
11 Increased shRNA abundance (Z-score > 2) GR00366-A-118 10.24 HLA-B
12 Increased shRNA abundance (Z-score > 2) GR00366-A-120 10.24 CCR1
13 Increased shRNA abundance (Z-score > 2) GR00366-A-125 10.24 IL10
14 Increased shRNA abundance (Z-score > 2) GR00366-A-128 10.24 IL10 TLR4
15 Increased shRNA abundance (Z-score > 2) GR00366-A-130 10.24 ADA2
16 Increased shRNA abundance (Z-score > 2) GR00366-A-132 10.24 IL10
17 Increased shRNA abundance (Z-score > 2) GR00366-A-137 10.24 C4A
18 Increased shRNA abundance (Z-score > 2) GR00366-A-147 10.24 CCR1
19 Increased shRNA abundance (Z-score > 2) GR00366-A-152 10.24 IL10
20 Increased shRNA abundance (Z-score > 2) GR00366-A-156 10.24 HLA-B
21 Increased shRNA abundance (Z-score > 2) GR00366-A-16 10.24 ADA2
22 Increased shRNA abundance (Z-score > 2) GR00366-A-161 10.24 C4A IL10
23 Increased shRNA abundance (Z-score > 2) GR00366-A-163 10.24 ADA2
24 Increased shRNA abundance (Z-score > 2) GR00366-A-169 10.24 TLR4
25 Increased shRNA abundance (Z-score > 2) GR00366-A-174 10.24 NOD2
26 Increased shRNA abundance (Z-score > 2) GR00366-A-177 10.24 NOD2
27 Increased shRNA abundance (Z-score > 2) GR00366-A-178 10.24 HLA-B
28 Increased shRNA abundance (Z-score > 2) GR00366-A-19 10.24 ADA2 C4A HLA-B NOD2
29 Increased shRNA abundance (Z-score > 2) GR00366-A-192 10.24 NOD2
30 Increased shRNA abundance (Z-score > 2) GR00366-A-195 10.24 NOD2 CCR1
31 Increased shRNA abundance (Z-score > 2) GR00366-A-196 10.24 CCR1
32 Increased shRNA abundance (Z-score > 2) GR00366-A-198 10.24 IL10
33 Increased shRNA abundance (Z-score > 2) GR00366-A-199 10.24 ADA2
34 Increased shRNA abundance (Z-score > 2) GR00366-A-210 10.24 NOD2 IL10
35 Increased shRNA abundance (Z-score > 2) GR00366-A-214 10.24 IL10
36 Increased shRNA abundance (Z-score > 2) GR00366-A-22 10.24 TLR4
37 Increased shRNA abundance (Z-score > 2) GR00366-A-25 10.24 IL10
38 Increased shRNA abundance (Z-score > 2) GR00366-A-31 10.24 HLA-B
39 Increased shRNA abundance (Z-score > 2) GR00366-A-36 10.24 NOD2 CCR1
40 Increased shRNA abundance (Z-score > 2) GR00366-A-43 10.24 C4A NOD2
41 Increased shRNA abundance (Z-score > 2) GR00366-A-47 10.24 ADA2
42 Increased shRNA abundance (Z-score > 2) GR00366-A-49 10.24 ADA2
43 Increased shRNA abundance (Z-score > 2) GR00366-A-52 10.24 ADA2 IL10
44 Increased shRNA abundance (Z-score > 2) GR00366-A-63 10.24 C4A CCR1
45 Increased shRNA abundance (Z-score > 2) GR00366-A-65 10.24 IL10
46 Increased shRNA abundance (Z-score > 2) GR00366-A-67 10.24 IL10
47 Increased shRNA abundance (Z-score > 2) GR00366-A-7 10.24 HLA-B
48 Increased shRNA abundance (Z-score > 2) GR00366-A-74 10.24 HLA-B
49 Increased shRNA abundance (Z-score > 2) GR00366-A-77 10.24 NOD2
50 Increased shRNA abundance (Z-score > 2) GR00366-A-8 10.24 C4A

MGI Mouse Phenotypes related to Behcet Syndrome:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.18 CCR1 ERAP1 FAS IL10 IL12A IL23R
2 homeostasis/metabolism MP:0005376 10.1 CCR1 CRP FAS IL10 IL12A IL23R
3 immune system MP:0005387 10.1 CCR1 CRP ERAP1 FAS IL10 IL12A
4 digestive/alimentary MP:0005381 10.01 CCR1 FAS IL10 IL23R NOD2 TLR4
5 liver/biliary system MP:0005370 9.7 CCR1 FAS IL10 MEFV TLR4 TNF
6 neoplasm MP:0002006 9.5 FAS IL10 IL12A IL23R TLR4 TNF
7 respiratory system MP:0005388 9.17 CCR1 FAS IL10 IL12A TLR4 TNF

Drugs & Therapeutics for Behcet Syndrome

Drugs for Behcet Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 101)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Prednisolone phosphate Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 302-25-0
2
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 50-24-8 5755
3
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 83-43-2 6741
4
Methylprednisolone hemisuccinate Approved Phase 4,Phase 3,Phase 2,Not Applicable 2921-57-5
5
Fluocinolone Acetonide Approved, Investigational, Vet_approved Phase 4 67-73-2 6215
6
Prednisolone hemisuccinate Experimental Phase 4,Phase 3,Phase 2,Not Applicable 2920-86-7
7 Prednisolone acetate Phase 4,Phase 3,Phase 2,Not Applicable
8 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Not Applicable
9 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Not Applicable
10 Hormones Phase 4,Not Applicable
11 Autonomic Agents Phase 4,Not Applicable
12 Antineoplastic Agents, Hormonal Phase 4,Not Applicable
13 Hormone Antagonists Phase 4,Not Applicable
14 Antiemetics Phase 4,Not Applicable
15 Methylprednisolone Acetate Phase 4,Phase 3,Phase 2,Not Applicable
16 Neuroprotective Agents Phase 4,Not Applicable
17 Gastrointestinal Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
18 glucocorticoids Phase 4,Not Applicable
19 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Not Applicable
20 Protective Agents Phase 4,Phase 2,Not Applicable
21 Pharmaceutical Solutions Phase 4,Phase 3,Phase 1
22 Omega 3 Fatty Acid Phase 4
23
Infliximab Approved Phase 3,Phase 1,Phase 2 170277-31-3
24
Adalimumab Approved Phase 3,Phase 2 331731-18-1 16219006
25
Apremilast Approved, Investigational Phase 3,Phase 2 608141-41-9 11561674
26
Cyclophosphamide Approved, Investigational Phase 3,Phase 2,Phase 1 6055-19-2, 50-18-0 2907
27
Miconazole Approved, Investigational, Vet_approved Phase 3 22916-47-8 4189
28 Antirheumatic Agents Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
29 Dermatologic Agents Phase 3,Phase 2,Phase 1,Not Applicable
30 Analgesics, Non-Narcotic Phase 3,Phase 2,Not Applicable
31 Immunologic Factors Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
32 Analgesics Phase 3,Phase 2,Not Applicable
33 Anti-Bacterial Agents Phase 3,Phase 2
34 Anti-Infective Agents Phase 3,Phase 2,Not Applicable
35 Anti-Inflammatory Agents, Non-Steroidal Phase 3,Phase 2,Not Applicable
36 Immunosuppressive Agents Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
37 Cyclosporins Phase 3
38 Angiogenesis Modulating Agents Phase 3,Phase 2
39 Angiogenesis Inhibitors Phase 3,Phase 2
40 Antineoplastic Agents, Alkylating Phase 3,Phase 1
41 Alkylating Agents Phase 3,Phase 1
42 Interferon-alpha Phase 3,Phase 2
43 Antiviral Agents Phase 3,Phase 2
44 interferons Phase 3,Phase 2
45 Antifungal Agents Phase 3
46 Interferon alpha-2 Phase 3
47 Calcineurin Inhibitors Phase 3,Phase 1
48 Antibodies Phase 3,Phase 2,Phase 1
49 Antibodies, Monoclonal Phase 3,Phase 2,Phase 1
50 Immunoglobulins Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 79)
# Name Status NCT ID Phase Drugs
1 The Efficacy of Methylprednisolone in the Treatment of Patients With Ocular Involvement in Behcet's Disease Unknown status NCT01306955 Phase 4 methylorednisolone
2 Flucinolone Acetonide Implant for Treating Refractory Ocular Behcet's Disease Unknown status NCT00720928 Phase 4 flucinolone acetonide
3 Trial to Study the Effects of Supplementary Omega-3 on Serum C-Reactive Protein Levels Terminated NCT00578578 Phase 4
4 Saline vs. Lactated Ringers for Emergency Department IV Fluid Resuscitation Completed NCT03133767 Phase 4 Lactated Ringer Solution;Normal Saline 0.9% Infusion Solution Bag
5 A Study to Evaluate Efficacy and Safety of Infliximab in Participant With Moderate-to-Severe Refractory Intestinal Behcet's Disease Completed NCT02505568 Phase 3 Infliximab
6 A Phase 3 Randomized, Double-blind Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) in Subjects With Active Behcet's Disease Active, not recruiting NCT02307513 Phase 3 Apremilast (CC-10004);Placebo
7 Efficacy and Safety Study of Gevokizumab to Treat Behcet's Disease Uveitis Terminated NCT02258867 Phase 3 Placebo;Gevokizumab
8 A Study of Adalimumab in Japanese Subjects With Intestinal Behçet's Disease Completed NCT01243671 Phase 3
9 Clinical Study of TA-650 in Patients With Behcet's Disease (BD) With Special Lesions Completed NCT01532570 Phase 3 TA-650
10 Induction Therapy With Anti-TNFα vs Cyclophosphamide in Severe Behçet Disease Not yet recruiting NCT03371095 Phase 3 Infliximab;Cyclophosphamide
11 Phase III Study in Refractory Behcet's Disease Completed NCT00995709 Phase 3 AIN457;AIN457;Placebo
12 Interferon α2a Versus Cyclosporine for Refractory Behçet`s Disease Uveitis Recruiting NCT03209219 Phase 3 Interferon Alfa-2A;Cyclosporine Pill
13 Interferon-alpha2a Versus Cyclosporin A for Severe Ocular Behcet`s Disease (INCYTOB) Completed NCT00167583 Phase 3 Cyclosporin A;Interferon-alpha2a
14 Efficacy of Gevokizumab in the Treatment of Patients With Behçet's Disease Uveitis (EYEGUARD™-B) Terminated NCT01965145 Phase 3 Gevokizumab;Placebo
15 Efficacy of Humira in Behcet Patients With Arthritis Completed NCT01497717 Phase 3 Adalimumab (Humira)
16 Safety and Efficacy of AIN457 in Patients With Active Non-infectious Uveitis Terminated NCT01095250 Phase 3 AIN457;AIN457;AIN457;Placebo
17 Thalidomide Versus Infliximab in New Onset Crohn's Disease With Poor Prognostic Factors Recruiting NCT03221166 Phase 3 Thalidomide;Infliximab
18 Long-term Safety of Gevokizumab in the Treatment of Patients With Chronic Non-infectious Uveitis (EYEGUARD-X) Terminated NCT02375685 Phase 3
19 An Open-label, Rollover Study Providing Continued Dosing of Gevokizumab in Order to Assess Long-term Gevokizumab Safety Data Terminated NCT02258854 Phase 3 Dose 2 gevokizumab
20 Tocilizumab for the Treatment of Behcet's Syndrome Terminated NCT01693653 Phase 2 Tocilizumab
21 Topical Pentoxifylline Gel on Behcet's Disease Oral Ulcers Not yet recruiting NCT03888846 Phase 2 Pentoxifylline;Colchicine
22 Colchicine Randomized Double-Blind Controlled Crossover Study in Behcet's Disease Completed NCT00700297 Phase 2 Colchicine;Placebo
23 A Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) in the Treatment of Behçet Disease Completed NCT00866359 Phase 2 Apremilast (CC-10004);Placebo
24 Anti IL-18 (GSK1070806) in Behcet's Disease Not yet recruiting NCT03522662 Phase 2 GSK1070806
25 Rituximab for the Treatment of Severe Ocular Manifestations of Behcet's Disease Completed NCT00664599 Phase 2 Rituximab;Cytotoxic Combination
26 Efficacy and Safety of Ustekinumab, a Human Monoclonal Anti-IL-12/IL-23 Antibody, in Patients With Behçet Disease Active, not recruiting NCT02648581 Phase 2 Subcutaneous Ustekinumab
27 Intravitreal Infliximab in Refractory Uveitis in Behcet's Disease: A Safety and Efficacy Clinical Study Completed NCT02620618 Phase 1, Phase 2 Intravitreal Infliximab
28 1 Year Canakinumab Treatment in Behcet's Disease Patients With Neurologic or Vascular Involvement Recruiting NCT02756650 Phase 2 drug administration
29 Low Dose Interferon Alpha Treatment for Oral Ulcers of Behcet's Disease Completed NCT00483184 Phase 2
30 HAT in Eye Complications of Behcet's Disease Completed NCT00001865 Phase 2 Daclizumab
31 Tocilizumab for the Treatment of Refractory Behcet's Uveitis Recruiting NCT03554161 Phase 2
32 A Pilot Study of XOMA 052 in Familial Cold Autoinflammatory Syndrome / Muckle-Wells Syndrome and Behcet's Disease Withdrawn NCT01211977 Phase 1, Phase 2 XOMA 052
33 Anakinra for Behcet s Disease Completed NCT01441076 Phase 1, Phase 2 Anakinra
34 Ilaris (Canakinumab) in the Schnitzler Syndrome Completed NCT01245127 Phase 2 Ilaris
35 Efficacy and Safety Study of Two Doses of Apremilast (CC-10004) In Japanese Subjects With Moderate-To-Severe Plaque-Type Psoriasis Completed NCT01988103 Phase 2 Apremilast;Apremilast;Placebo
36 Randomized Trial Comparing Efficacy of Adalimumab, Anakinra and Tocilizumab in Non-infectious Refractory Uveitis Recruiting NCT02929251 Phase 2 Anakinra;Tocilizumab;Adalimumab
37 Induction of Regulatory t Cells by Low Dose il2 in Autoimmune and Inflammatory Diseases Recruiting NCT01988506 Phase 2 Interleukin 2
38 Stem Cell Transplantation for the Treatment of Knee Osteoarthritis Unknown status NCT00550524 Phase 1
39 Stem Cell Transplantation in Ocular Lesions of Behcet's Disease Terminated NCT00550498 Phase 1
40 Hematopoietic Stem Cell Support in Vasculitis Terminated NCT00278512 Phase 1 Cyclophosphamide;ATG (rabbit);G-CSF;Campath-1h;Fludarabine;Tacrolimus;Mesna
41 Etanercept: Single Blind Control Study in Ocular Manifestations of Behcet's Disease Unknown status NCT00931957 Not Applicable Etanercept, Methotrexate, Prednisolone
42 The Clinical and Biological Effects Of The Use Of Probiotic VSL#3 In Patients With Oral Lichen Planus Unknown status NCT03052179 Not Applicable
43 The Serum Angiotensin Converting Enzyme and Lysozyme Levels in Patients Non-infectious and Infectious Uveitis Unknown status NCT02627209 Not Applicable
44 Causes of Visual Loss in Retinal Disease Unknown status NCT01613963 Immunosuppressive Agents
45 Behçet's Disease Overall Damage Index Recruiting NCT03803462
46 Evaluation of Fibromyalgia With Disease Activity and Clinical Findings in Women With Behçet's Disease Completed NCT03543709
47 Frequency of Fibromyalgia in Behcet Disease Recruiting NCT03514056
48 Inactivity Behavior and Exercise Bariers in Patients With Behçet Disease Recruiting NCT03837236 Not Applicable
49 Psychological Symptoms in Patients With Behcet's Disease by SCL90-R Completed NCT00699985
50 Assessment of Disease Activity in Behcet by Complete Blood Count Not yet recruiting NCT03747354 Not Applicable

Search NIH Clinical Center for Behcet Syndrome

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Behcet Syndrome cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Behcet Syndrome:
Bone marrow-derived stem cells for treatment of ocular lesions Behcet's disease
Embryonic/Adult Cultured Cells Related to Behcet Syndrome:
Bone marrow-derived stem cells PMIDs: 21199472 23773637

Cochrane evidence based reviews: behcet syndrome

Genetic Tests for Behcet Syndrome

Anatomical Context for Behcet Syndrome

MalaCards organs/tissues related to Behcet Syndrome:

42
Eye, Skin, Brain, Spinal Cord, Bone, Testes, T Cells

Publications for Behcet Syndrome

Articles related to Behcet Syndrome:

(show top 50) (show all 729)
# Title Authors Year
1
Genotyping of Italian patients with Behçet syndrome identified two novel ERAP1 polymorphisms using sequencing-based approach. ( 30742879 )
2019
2
Deep vein thrombosis induced by vasculitis in the Behçet's syndrome. ( 30707181 )
2019
3
Assessment of deep venous thrombosis in the lower extremity in Behçet's syndrome: MR venography versus Doppler ultrasonography. ( 30712149 )
2019
4
Deep vein thrombosis induced by vasculitis in the Behçet's syndrome. ( 30730431 )
2019
5
Update on the treatment of Behçet's syndrome. ( 30684097 )
2019
6
Phenotypes in Behçet's syndrome. ( 30747365 )
2019
7
The right place of interleukin-1 inhibitors in the treatment of Behçet's syndrome: a systematic review. ( 30799530 )
2019
8
Distribution of rs17482078 and rs27044 ERAP1 polymorphisms in a group of Italian Behçet's syndrome patients: a preliminary case-control study. ( 30820838 )
2019
9
Nervous system involvement in Behçet's syndrome. ( 30407226 )
2019
10
Treatment of deep vein thrombosis in a patient with Behçet syndrome using ultrasound-accelerated catheter-directed thrombolysis. ( 30398005 )
2018
11
Surgical treatment of intestinal perforation in Behçet Syndrome: an unusual presentation. ( 30574248 )
2018
12
Preoperative Misdiagnosis of Intestinal Behçet's Syndrome as Crohn's Disease Based on Superficial Colonoscopic Biopsies: Case Report and Systematic Review. ( 30151660 )
2018
13
Primary optic neuropathy in Behçet's syndrome. ( 29985083 )
2018
14
Adalimumab for Venous Thrombosis in Behçet's Syndrome: Further Questions need to be answered. ( 30548210 )
2018
15
Is Warfarin Indicated in Behcet's Syndrome Associated with Thrombosis? Reflections on Treatment and Death of a Patient. ( 29271390 )
2018
16
Vascular Behçet's syndrome: an update. ( 30499073 )
2018
17
Concurrent presence of buccal mucosal and ophthalmologic lesions in Behcet's syndrome. ( 30510645 )
2018
18
Triggering agents and microbiome as environmental factors on Behçet's syndrome. ( 30523495 )
2018
19
No Family Clustering in Behçet’s Syndrome ( 30582319 )
2018
20
Faecal but not serum calprotectin levels look promising in predicting active disease in Behçet's syndrome patients with gastrointestinal involvement. ( 30582504 )
2018
21
Behçet's syndrome and psychiatric involvement: is it a primary or secondary feature of the disease? ( 30582513 )
2018
22
Highlights of the 18th International Conference on Behçet's syndrome. ( 30582514 )
2018
23
One year in review 2018: Behçet's syndrome. ( 30582516 )
2018
24
Use of Apremilast for Aphthous Ulcers in a Patient With Behçet’s Syndrome ( 30586267 )
2018
25
Fatigue in patients with Behçet's syndrome: relationship with quality of life, depression, anxiety, disability and disease activity. ( 26913703 )
2018
26
Outcomes of Patients with Behçet's Syndrome after Pulmonary Endarterectomy. ( 28810271 )
2018
27
2018 update of the EULAR recommendations for the management of Behçet's syndrome. ( 29625968 )
2018
28
Hemoptysis in Behçet's syndrome: from bedside to bench? ( 29736629 )
2018
29
Behçet's Syndrome and Nervous System Involvement. ( 29789966 )
2018
30
Management of skin, mucosa and joint involvement of Behçet's syndrome: A systematic review for update of the EULAR recommendations for the management of Behçet's syndrome. ( 29954598 )
2018
31
Surgical Treatment of Pulmonary Complications in Behçet's Syndrome. ( 30031945 )
2018
32
New Insights into Behçet's Syndrome Metabolic Reprogramming: Citrate Pathway Dysregulation. ( 30050389 )
2018
33
Management of major organ involvement of Behçet's syndrome: a systematic review for update of the EULAR recommendations. ( 30107448 )
2018
34
Efficacy of the anti-IL 17 secukinumab in refractory Behçet's syndrome: A preliminary study. ( 30213443 )
2018
35
Behcet's Syndrome: Fear Not the Unknown. ( 30236452 )
2018
36
Behçet's syndrome as a tool to dissect the mechanisms of thrombo-inflammation: clinical and pathogenetic aspects. ( 30472725 )
2018
37
Exacerbation of Behçet's syndrome and familial Mediterranean fever with menstruation. ( 29148415 )
2017
38
Infliximab for uveitis of Behçet's syndrome: a trend for earlier initiation. ( 29148418 )
2017
39
Behcet's syndrome in nonendemic regions. ( 27684358 )
2017
40
Neurological complications of Behçet's syndrome. ( 28283819 )
2017
41
Adherence to guidelines for the treatment of Behçet's syndrome in New York and Amsterdam. ( 28406760 )
2017
42
Behçet's syndrome and health-related quality of life: influence of symptoms, lifestyle and employment status. ( 28598773 )
2017
43
Behçet's syndrome: providing integrated care. ( 28860798 )
2017
44
To immunosuppress or not: Behcet's syndrome presenting as an eosinophilic pleural effusion. ( 28869232 )
2017
45
Qualitative study: the experience and impact of living with Behcet's syndrome. ( 28934765 )
2017
46
One year in review 2017: Behçet's syndrome. ( 28980900 )
2017
47
Pure red aplasia induced by sodium valproate in a patient with Behçet's syndrome. ( 29148419 )
2017
48
A Patient with Neuro-Behçet's Syndrome Presenting with Peripheral Nerve Involvement. ( 29321715 )
2017
49
Serum Vitamin B12, Homocysteine and Methylmalonic Acid Levels in Patients With Parenchymal Neuro-Behçet's Syndrome. ( 30375556 )
2017
50
Delayed Vasospasm after Aneurysmal Subarachnoid Hemorrhage in Behcet Syndrome. ( 27114963 )
2016

Variations for Behcet Syndrome

ClinVar genetic disease variations for Behcet Syndrome:

6 (show all 34)
# Gene Variation Type Significance SNP ID Assembly Location
1 TNFRSF1A NM_001065.3(TNFRSF1A): c.596T> C (p.Ile199Thr) single nucleotide variant Uncertain significance rs104895247 GRCh37 Chromosome 12, 6440048: 6440048
2 TNFRSF1A NM_001065.3(TNFRSF1A): c.596T> C (p.Ile199Thr) single nucleotide variant Uncertain significance rs104895247 GRCh38 Chromosome 12, 6330882: 6330882
3 NOD2 NM_022162.2(NOD2): c.2446G> A single nucleotide variant Pathogenic rs886040969 GRCh37 Chromosome 16, 50746268: 50746268
4 NOD2 NM_022162.2(NOD2): c.2446G> A single nucleotide variant Pathogenic rs886040969 GRCh38 Chromosome 16, 50712357: 50712357
5 TNFRSF1A NM_001065.3(TNFRSF1A): c.463C> T (p.His155Tyr) single nucleotide variant Pathogenic rs886039866 GRCh37 Chromosome 12, 6442542: 6442542
6 TNFRSF1A NM_001065.3(TNFRSF1A): c.463C> T (p.His155Tyr) single nucleotide variant Pathogenic rs886039866 GRCh38 Chromosome 12, 6333376: 6333376
7 NOD2 NM_022162.2(NOD2): c.2197G> T (p.Val733Leu) single nucleotide variant Pathogenic rs746055479 GRCh38 Chromosome 16, 50712108: 50712108
8 NOD2 NM_022162.2(NOD2): c.2197G> T (p.Val733Leu) single nucleotide variant Pathogenic rs746055479 GRCh37 Chromosome 16, 50746019: 50746019
9 NOD2 NM_022162.2(NOD2): c.241C> G (p.Leu81Val) single nucleotide variant Pathogenic rs34936594 GRCh37 Chromosome 16, 50733566: 50733566
10 NOD2 NM_022162.2(NOD2): c.241C> G (p.Leu81Val) single nucleotide variant Pathogenic rs34936594 GRCh38 Chromosome 16, 50699655: 50699655
11 NOD2 NM_022162.2(NOD2): c.1045C> T (p.Leu349Phe) single nucleotide variant Pathogenic rs752615209 GRCh38 Chromosome 16, 50710956: 50710956
12 NOD2 NM_022162.2(NOD2): c.1045C> T (p.Leu349Phe) single nucleotide variant Pathogenic rs752615209 GRCh37 Chromosome 16, 50744867: 50744867
13 PSTPIP1 NM_003978.4(PSTPIP1): c.364G> A (p.Val122Ile) single nucleotide variant Uncertain significance rs886041107 GRCh37 Chromosome 15, 77320202: 77320202
14 PSTPIP1 NM_003978.4(PSTPIP1): c.364G> A (p.Val122Ile) single nucleotide variant Uncertain significance rs886041107 GRCh38 Chromosome 15, 77027861: 77027861
15 PSTPIP1 NM_003978.4(PSTPIP1): c.865G> C (p.Asp289His) single nucleotide variant Pathogenic rs774164456 GRCh38 Chromosome 15, 77032888: 77032888
16 PSTPIP1 NM_003978.4(PSTPIP1): c.865G> C (p.Asp289His) single nucleotide variant Pathogenic rs774164456 GRCh37 Chromosome 15, 77325229: 77325229
17 PSTPIP1 NM_003978.4(PSTPIP1): c.203C> T (p.Thr68Met) single nucleotide variant Likely benign rs201872851 GRCh38 Chromosome 15, 77018522: 77018522
18 PSTPIP1 NM_003978.4(PSTPIP1): c.203C> T (p.Thr68Met) single nucleotide variant Likely benign rs201872851 GRCh37 Chromosome 15, 77310863: 77310863
19 ADA2 NM_001282225.1(ADA2): c.145C> T (p.Arg49Trp) single nucleotide variant Uncertain significance rs199614299 GRCh38 Chromosome 22, 17209533: 17209533
20 ADA2 NM_001282225.1(ADA2): c.145C> T (p.Arg49Trp) single nucleotide variant Uncertain significance rs199614299 GRCh37 Chromosome 22, 17690423: 17690423
21 ADA2 NM_001282225.1(ADA2): c.927G> A (p.Met309Ile) single nucleotide variant Likely benign rs146597836 GRCh38 Chromosome 22, 17189987: 17189987
22 ADA2 NM_001282225.1(ADA2): c.927G> A (p.Met309Ile) single nucleotide variant Likely benign rs146597836 GRCh37 Chromosome 22, 17670877: 17670877
23 ADA2 NM_001282225.1(ADA2): c.740C> T (p.Ala247Val) single nucleotide variant Pathogenic rs750868279 GRCh38 Chromosome 22, 17203576: 17203576
24 ADA2 NM_001282225.1(ADA2): c.740C> T (p.Ala247Val) single nucleotide variant Pathogenic rs750868279 GRCh37 Chromosome 22, 17684466: 17684466
25 MEFV NM_000243.2(MEFV): c.1211A> G (p.His404Arg) single nucleotide variant Pathogenic rs755659290 GRCh38 Chromosome 16, 3249480: 3249480
26 MEFV NM_000243.2(MEFV): c.1211A> G (p.His404Arg) single nucleotide variant Pathogenic rs755659290 GRCh37 Chromosome 16, 3299480: 3299480
27 MEFV NM_000243.2(MEFV): c.1099C> G (p.Leu367Val) single nucleotide variant Pathogenic rs1057519328 GRCh38 Chromosome 16, 3249592: 3249592
28 MEFV NM_000243.2(MEFV): c.1099C> G (p.Leu367Val) single nucleotide variant Pathogenic rs1057519328 GRCh37 Chromosome 16, 3299592: 3299592
29 TNFRSF1A NM_001065.3(TNFRSF1A): c.935G> A (p.Arg312Lys) single nucleotide variant Conflicting interpretations of pathogenicity rs200900510 GRCh38 Chromosome 12, 6329900: 6329900
30 TNFRSF1A NM_001065.3(TNFRSF1A): c.935G> A (p.Arg312Lys) single nucleotide variant Conflicting interpretations of pathogenicity rs200900510 GRCh37 Chromosome 12, 6439066: 6439066
31 ADA2 NM_001282225.1(ADA2): c.1045G> A (p.Val349Ile) single nucleotide variant Benign rs74317375 GRCh37 Chromosome 22, 17669265: 17669265
32 ADA2 NM_001282225.1(ADA2): c.1045G> A (p.Val349Ile) single nucleotide variant Benign rs74317375 GRCh38 Chromosome 22, 17188375: 17188375
33 MEFV NM_000243.2(MEFV): c.332G> A (p.Gly111Glu) single nucleotide variant Pathogenic rs751454741 GRCh37 Chromosome 16, 3304736: 3304736
34 MEFV NM_000243.2(MEFV): c.332G> A (p.Gly111Glu) single nucleotide variant Pathogenic rs751454741 GRCh38 Chromosome 16, 3254736: 3254736

Copy number variations for Behcet Syndrome from CNVD:

7
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 241985 8 6835170 6856724 Copy number DEFA1 Behcet''s disease

Expression for Behcet Syndrome

Search GEO for disease gene expression data for Behcet Syndrome.

Pathways for Behcet Syndrome

Pathways related to Behcet Syndrome according to GeneCards Suite gene sharing:

(show all 37)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.79 ADA2 C4A CCR1 CRP ERAP1 HLA-B
2
Show member pathways
13.34 CCR1 FAS IL10 IL12A IL23R STAT4
3
Show member pathways
13.32 CCR1 HLA-B IL10 IL12A IL23R NOD2
4
Show member pathways
13.26 CCR1 FAS IL10 IL12A IL23R TNF
5
Show member pathways
12.91 CCR1 FAS HLA-B STAT4 TLR4 TNF
6
Show member pathways
12.84 FAS IL10 IL12A MEFV NOD2 PSTPIP1
7
Show member pathways
12.77 C4A FAS HLA-B IL10 IL12A KLRC4
8
Show member pathways
12.58 FAS IL12A TLR4 TNF TNFRSF1A
9 12.54 FAS IL10 STAT4 TNF TNFRSF1A
10
Show member pathways
12.54 FAS HLA-B IL12A TLR4 TNF TNFRSF1A
11
Show member pathways
12.49 IL10 IL12A IL23R NOD2 STAT4 TLR4
12
Show member pathways
12.38 FAS IL10 PSTPIP1 TNF
13
Show member pathways
12.37 CCR1 IL10 IL12A IL23R STAT4
14
Show member pathways
12.19 IL10 IL12A TLR4 TNF TNFRSF1A
15
Show member pathways
12.15 FAS STAT4 TLR4 TNF TNFRSF1A
16 12.1 IL10 IL12A NOD2 TLR4 TNF TNFRSF1A
17 11.96 IL10 IL12A IL23R TNF
18 11.93 FAS NOD2 TNF TNFRSF1A
19 11.85 IL10 IL12A TLR4 TNF
20 11.83 TLR4 TNF TNFRSF1A
21 11.82 CCR1 IL10 IL12A IL23R STAT4
22 11.75 IL10 IL12A IL23R TNF
23 11.71 IL10 IL12A TNF
24 11.69 IL10 IL12A TNF
25 11.69 TLR4 TNF TNFRSF1A
26 11.56 IL12A TLR4 TNF
27 11.55 TLR4 TNF TNFRSF1A
28
Show member pathways
11.55 IL10 IL12A IL23R STAT4 TLR4 TNF
29 11.54 C4A IL10 IL12A TLR4 TNF
30 11.52 FAS TNF TNFRSF1A
31 11.49 IL12A TLR4 TNF
32 11.49 IL10 IL12A TLR4 TNF
33 11.45 FAS TNF TNFRSF1A
34 11.34 IL10 TLR4 TNF
35 11.33 FAS IL10 IL12A TNF
36 11.1 NOD2 TNF TNFRSF1A
37 10.71 CCR1 IL10 IL12A TNF TNFRSF1A

GO Terms for Behcet Syndrome

Cellular components related to Behcet Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.76 ADA2 C4A CRP ERAP1 IL10 IL12A
2 extracellular region GO:0005576 9.61 ADA2 C4A CRP ERAP1 FAS IL10
3 cell surface GO:0009986 9.1 FAS HLA-B NOD2 TLR4 TNF TNFRSF1A

Biological processes related to Behcet Syndrome according to GeneCards Suite gene sharing:

(show all 49)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.98 CCR1 NOD2 TLR4 TNF
2 innate immune response GO:0045087 9.91 C4A CRP IL23R MEFV NOD2 PSTPIP1
3 negative regulation of inflammatory response GO:0050728 9.88 IL10 MEFV TNFRSF1A
4 positive regulation of I-kappaB kinase/NF-kappaB signaling GO:0043123 9.88 NOD2 TLR4 TNF TNFRSF1A
5 defense response to bacterium GO:0042742 9.88 IL10 NOD2 TLR4 TNF TNFRSF1A
6 defense response to Gram-positive bacterium GO:0050830 9.87 CRP IL12A TNF
7 immune response GO:0006955 9.87 CCR1 FAS HLA-B IL10 IL12A TLR4
8 positive regulation of JNK cascade GO:0046330 9.86 NOD2 TLR4 TNF
9 response to lipopolysaccharide GO:0032496 9.86 IL10 IL12A IL23R TLR4
10 cellular response to mechanical stimulus GO:0071260 9.85 FAS TLR4 TNFRSF1A
11 positive regulation of inflammatory response GO:0050729 9.85 TLR4 TNF TNFRSF1A
12 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.82 IL12A IL23R TNFRSF1A
13 regulation of inflammatory response GO:0050727 9.82 NOD2 TLR4 TNF
14 apoptotic signaling pathway GO:0097190 9.8 FAS TLR4 TNF
15 I-kappaB kinase/NF-kappaB signaling GO:0007249 9.8 TLR4 TNF TNFRSF1A
16 positive regulation of interleukin-6 production GO:0032755 9.79 NOD2 TLR4 TNF
17 immune system process GO:0002376 9.76 C4A ERAP1 HLA-B IL23R MEFV NOD2
18 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.74 NOD2 TLR4 TNF
19 interleukin-12-mediated signaling pathway GO:0035722 9.72 IL10 IL12A STAT4
20 extrinsic apoptotic signaling pathway GO:0097191 9.71 FAS IL12A TNF
21 cellular response to lipopolysaccharide GO:0071222 9.71 IL10 NOD2 TLR4 TNF
22 negative regulation of growth of symbiont in host GO:0044130 9.7 IL10 TNF
23 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.7 IL10 TNF
24 positive regulation of nitric-oxide synthase biosynthetic process GO:0051770 9.7 NOD2 TLR4
25 positive regulation of interleukin-17 production GO:0032740 9.69 IL23R NOD2
26 negative regulation of interleukin-12 production GO:0032695 9.69 IL10 MEFV
27 negative regulation of interleukin-6 production GO:0032715 9.69 IL10 TLR4 TNF
28 negative regulation of interleukin-17 production GO:0032700 9.68 IL12A TLR4
29 interleukin-35-mediated signaling pathway GO:0070757 9.68 IL12A STAT4
30 positive regulation of interleukin-8 biosynthetic process GO:0045416 9.67 TLR4 TNF
31 positive regulation of interleukin-8 production GO:0032757 9.67 NOD2 TLR4 TNF
32 interleukin-23-mediated signaling pathway GO:0038155 9.66 IL23R STAT4
33 negative regulation of lipid storage GO:0010888 9.66 CRP TNF
34 positive regulation of ceramide biosynthetic process GO:2000304 9.65 TNF TNFRSF1A
35 positive regulation of lymphocyte proliferation GO:0050671 9.65 IL12A TLR4
36 death-inducing signaling complex assembly GO:0071550 9.64 TNF TNFRSF1A
37 endothelial cell apoptotic process GO:0072577 9.63 IL10 TNF
38 positive regulation of T cell mediated cytotoxicity GO:0001916 9.63 HLA-B IL12A IL23R
39 positive regulation of MHC class II biosynthetic process GO:0045348 9.61 IL10 TLR4
40 regulation of establishment of endothelial barrier GO:1903140 9.61 TNF TNFRSF1A
41 positive regulation of osteoclast differentiation GO:0045672 9.61 CCR1 IL23R TNF
42 necroptotic signaling pathway GO:0097527 9.6 FAS TNF
43 negative regulation of cytokine secretion involved in immune response GO:0002740 9.59 IL10 TNF
44 positive regulation of NK T cell activation GO:0051135 9.58 IL12A IL23R
45 positive regulation of interferon-gamma production GO:0032729 9.56 IL12A IL23R TLR4 TNF
46 receptor biosynthetic process GO:0032800 9.52 IL10 TNF
47 cytokine-mediated signaling pathway GO:0019221 9.5 CCR1 IL10 IL12A IL23R STAT4 TNF
48 interferon-gamma production GO:0032609 9.39 TLR4
49 inflammatory response GO:0006954 9.32 C4A CCR1 CRP IL10 IL23R MEFV

Molecular functions related to Behcet Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.5 CRP FAS MEFV PSTPIP1 STAT4 TLR4
2 complement component C1q binding GO:0001849 9.16 C4A CRP
3 interleukin-12 receptor binding GO:0005143 8.62 IL12A IL23R

Sources for Behcet Syndrome

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....